Safety Profile of Montelukast and Levocetirizine in Myasthenia Gravis
Mechanistic Safety
Levocetirizine is a second‑generation H1 antihistamine that does not possess anticholinergic activity, so it is unlikely to impair neuromuscular transmission in patients with myasthenia gravis. 1
Montelukast blocks leukotriene receptors and has no known interaction with acetylcholine‑receptor function or the neuromuscular junction, supporting its safe use in myasthenia gravis. 2
Elderly Patient Considerations
- In older adults, H1 antihistamines with anticholinergic properties are linked to cognitive decline; levocetirizine’s lack of significant anticholinergic effects makes it a safer option for this population. 1
Peri‑operative Management
- Patients with myasthenia gravis who require neuromuscular blockade for surgery should receive reduced doses of blocking agents and be monitored closely for respiratory muscle weakness. 3
Management Recommendations for Myasthenia Gravis Across All Ages
Diagnostic Workup
- All grades of myasthenia gravis require systematic evaluation and timely intervention because the disease can progress to respiratory compromise regardless of severity 4, 5, 6.
Medication Precautions in Older Adults
- Clinicians should avoid drugs known to exacerbate myasthenia gravis—such as β‑blockers, intravenous magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics—especially in patients with comorbidities that increase vulnerability 4, 5, 6.
Antibiotic Selection for Myasthenia Gravis Patients
First‑Line Beta‑Lactam Antibiotics
- Amoxicillin and amoxicillin‑clavulanate are regarded as among the safest oral agents for patients with myasthenia gravis, showing a low incidence of drug‑related exacerbations in clinical studies. 7, 8, 9
- Cephalosporins (e.g., cefazolin, cefuroxime, ceftriaxone, cefotaxime) are appropriate alternatives with favorable safety profiles for myasthenia gravis patients, based on multiple cohort analyses. 7, 8, 9
- Penicillin G and penicillin V remain safe choices for infections caused by susceptible organisms in myasthenia gravis, with no increased risk of crisis reported in the cited literature. 7, 8, 9
Second‑Line Non‑Beta‑Lactam Options (when beta‑lactams are unsuitable)
- Clindamycin can be employed for anaerobic coverage in myasthenia gravis patients, although it is bacteriostatic and resistance potential should be considered. 7, 8, 9
- Trimethoprim‑sulfamethoxazole may be used as an alternative agent, though efficacy data in this population are limited. 7, 8, 9